TABLE 27Characteristics of the economic evaluation

AuthorGhatnekar and colleagues (2010)15
Publication year2010
CountrySweden
Funding sourceBMS
Study typeCost–utility analysis
PerspectiveSocietal
Study populationPatients confirmed to be resistant to lower doses of imatinib (≤ 600 mg)
Intervention(s)Dasatinib: 140 mg/day

Imatinib: 800 mg/day
Intervention effectResponse to treatment

No response: dasatinib 7.9% patients, imatinib 18.4% patients

CHR: dasatinib 57.4% patients, imatinib 53.1% patients

PCyR: dasatinib 13.9% patients, imatinib 20.4% patients

CCyR: dasatinib 20.8% patients, imatinib 8.2% patients
Intervention costMonthly costs (€)

Imatinib 800 mg/day 4869

Dasatinib 140 mg/day 4239
Currency base€ (2008)
Model type, health statesMarkov model with patients starting in CP, who after 12-week initial treatment period can progress to AP then BC then death; probabilities by response to treatment
Time horizonLifetime
Baseline cohortPatients in CP-CML confirmed to be resistant to lower doses of imatinib (≤ 600 mg) aged 60 years
Base-case resultsDasatinibHDI
Total direct costs€350,960€346,507
Total societal costs€504,532€500,281
LYs6.375.69
QALYs5.194.57
ICER (LYs, societal)€6332
ICER (QALYs, societal)€6880
ICER (LYs, direct)€6645
ICER (QALYs, direct)€7207

AP, accelerated phase; BC, blast crisis; CCyR, complete cytogenetic response; CP, chronic phase; CP-CML, chronic-phase chronic myeloid leukaemia; HDI, high-dose imatinib; LY, life-year; PCyR, partial cytogenetic response; QALY, quality-adjusted life-year.

PCyR typically defined as between 1% and 35% of Philadelphia-positive chromosomes in metaphase in bone marrow.

From: 4, Economic analysis

Cover of Dasatinib, High-Dose Imatinib and Nilotinib for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation
Dasatinib, High-Dose Imatinib and Nilotinib for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 16.23.
Loveman E, Cooper K, Bryant J, et al.
Southampton (UK): NIHR Journals Library; 2012 May.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.